Allergen immunotherapy for house dust mite-induced rhinitis: prescriptive criteria
Main Article Content
allergic rhinitis, onset of asthma, allergen immunotherapy, ait, prescriptive criteria, risk factors for asthma
Allergic rhinitis (AR) is a very common disease. In most cases, therapy is based on symptomatic drugs, while allergen immunotherapy (AIT), which is the only one to act on the cause of the disease, is reserved for patients with a greater burden of disease. In particular, the possible evolution towards asthma substantiates the use of AIT, but requires the availability of diagnostic indices related to the risk of developing asthma. We analyzed the available literature on risk factors for onset of asthma in patients with AR, including bronchial hyperresponsiveness, uncovering by respiratory function tests of airway impairment, measurement of fractioned exhaled nitric oxide, given IgE sensitization pattern, and respiratory infections detected by nasal mucus samples or by particular microbiomes. Most of these risk predictors have been investigated too little or do not have consistent results, while various studies have confirmed that early bronchial impairment in AR patients, particularly concerning small airways, should be considered as prescriptive criteria for AIT.
2) Jutel M, Agache I, Bonini S, et al. International Consensus on Allergen Immunotherapy II: Mechanisms, standardization and pharmacoeconomics. J Allergy Clin Immunol. 2016 Feb;137(2):358-68.
3) Jacobsen L, Niggemann B, Dreborg S, et al. Speciffic immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow on the PAT study. Allergy 2007;62:943-8
4) Schmitt J, Schwarz K, Stadler E, Wustenberg EG. Allergy immunotherapy for allergic rhinitis effectively prevents asthma: results from a large retrospective cohort study. J Allergy Clin Immunol. 2015;136:1511-1516.
5) Zielen S, Devillier P, Heinrich J, Richter H, Wahn U. Sublingual immunotherapy provides long-term relief in allergic rhinitis and reduces the risk of asthma: A retrospective, real-world database analysis. Allergy. 2018;73(1):165-177.
6) Wahn U, Bachert C, Heinrich J, Richter H, Zielen S. Real world benefits of allergen immunotherapy for birch pollen-associated allergic rhinitis and asthma. Allergy. 2019 Mar;74(3):594-604.
7) Lake IR, Jones NR, Agnew M, et al. Climate Change and Future Pollen Allergy in Europe. Environ Health Perspect. 2017;125(3):385-391
8) Kuehr J, Frischer T, Meinert R, et al. Sensitization to mite allergens is a risk factor for early and late onset of asthma and for persistence of asthmatic signs in children. J Allergy Clin Immunol . 1995 Mar;95(3):655-62.
9) Bousquet J, Dahl R, N Khaltaev N. Global Alliance against Chronic Respiratory Diseases. Eur Respir J. 2007;29(2):233-9.
10) Townley RG, Ryo UY, Kolotkin BM, Kang B. Bronchial sensitivity to methacholine in current and former asthmatic and allergic rhinitis patients and control subjects. J Allergy Clin Immunol 1975; 56(6):429-42.
11) Madonini E, Briatico Vangosa G, Pappacoda A, Maccagni G, Cardani A, Saporiti F. Seasonal increase of bronchial reactivity in allergic rhinitis. J Allergy Clin Immunol 1987; 79(2):358-63.
12) Braman SS, Barrows AA, DeCotiis BA, Settipane GA, Corrao WM. Airway hyperresponsiveness in allergic rhinitis. A risk factor for asthma. Chest 1987; 91(5):671-4.
13) Porsbjerg C, von Linstow ML, Ulrik C, Nepper-Christensen S, Backer V. Risk factors for onset of asthma: a 12-year prospective follow-up study. Chest. 2006;129(2):309-16.
14) Ciprandi G, Signori A, Tosca MA, Cirillo I. Spirometric abnormalities in patients with allergic rhinitis: indicator of an “asthma march? Am J Rhinol Allergy. 2011;25(5):181-85.
15) Ciprandi G, Cirillo I, Signori A. Impact of allergic rhinitis on bronchi: an 8-year follow-up study. Am J Rhinol Allergy. 2011 Mar-Apr;25(2):e72-6.
16) Skylogianni E , Triga M, Douros K, et al. Small-airway dysfunction precedes the development of asthma in children with allergic rhinitis. Allergol Immunopathol (Madr) 2018;46(4):313-321.
17) Ciprandi G, Cirillo I. The pragmatic role of FEF25-75 in asymptomatic subjects, allergic rhinitis, asthma, and in military setting. Expert Rev Respir Med. 2019; 13(12):1147-1151.
18) Ciprandi G, Cirillo I, Pistorio A. Impact of allergic rhinitis on asthma: effects on spirometric parameters. Allergy 2008; 63(3):255-60
19) Ciprandi G, Capasso M. Association of childhood perennial allergic rhinitis with subclinical airflow limitation. Clin Exp Allergy 2010;40:398-402
20) Muntean IA, Bocsan IC, Vesa S, et al. Could FeNO Predict Asthma in Patients with House Dust Mites Allergic Rhinitis? Medicina (Kaunas). 2020. 14;56(5):235.
21) Posa D, Perna S, Resch Y, et al. Evolution and predictive value of IgE responses toward a comprehensive panel of house dust mite allergens during the first 2 decades of life. J Allergy Clin Immunol. 2017;139(2):541-549.
22) Kusel MM, de Klerk NH, Tatiana Kebadze T, et al. Early-life respiratory viral infections, atopic sensitization, and risk of subsequent development of persistent asthma. J Allergy Clin Immunol. 2007;119(5):1105-10.
23) Tang HF, Lang A, Teo SM, et al. Developmental patterns in the nasopharyngeal microbiome during infancy are associated with asthma risk. J Allergy Clin Immunol. 2020. Epub Ahead of Print.
24) Elías Hernández MT, Sánchez Gil R, Cayuela Domínguez A, et al. Risk factors for bronchial asthma in patients with rhinitis. Arch Bronconeumol. 2001;37(10):429-34.
25) Brozek G, Lawson J, Szumilas D, Zejda J. Increasing prevalence of asthma, respiratory symptoms, and allergic diseases: Four repeated surveys from 1993-2014. Respir Med. 2015;109(8):982-90